Drug Profile
Research programme: G protein-coupled receptor modulator antibody therapeutics - Sosei Heptares/Kymab
Alternative Names: GPCR modulator monoclonal antibodies - Sosei Heptares/Kymab; GPCR targeting antibody therapeutics - Sosei Heptares/Kymab; KY 1062Latest Information Update: 03 Mar 2022
Price :
$50
*
At a glance
- Originator Heptares Therapeutics; Kymab
- Developer Kymab; Sosei Heptares
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 03 Mar 2022 Preclinical development is ongoing in Cancer in United Kingdom (Parenteral) (Sosei Heptares pipeline, March 2022)
- 28 Feb 2022 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
- 09 Apr 2021 Kymab has been acquired by Sanofi